Cd30+ cutaneous lymphoproliferative disorders: The stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma

Liu, Howard L.; Hoppe, Richard T.; Köhler, Sabine; Harvell, Jeff D.; Reddy, Sunil; Kim, Youn H.

doi:10.1016/s0190-9622(03)02484-8

Cited by 272 publications

(310 citation statements)

References 26 publications

Supporting

Mentioning

266

Contrasting

Unclassified

Order By: Relevance

“…4,[8][9][10] PCALCL can be classified as: T-(CD3+), B-(CD20+) or null-(CD3-, CD20-) cell immunophenotype. 5,11,14,15 Since our patient is CD3-and CD20-, she is classified under null-cell type of PCALCL.…”

Section: Discussionmentioning

confidence: 99%

“…5,8,[13][14][15] PCALCL is uncommon before age 20, with a peak at age 60. 4,14,15 It is about twice as common in men as in women, with a male to female ratio of 1.5 to 2.0:1.…”

Section: Discussionmentioning

confidence: 99%

“…5,8,[13][14][15] PCALCL is uncommon before age 20, with a peak at age 60. 4,14,15 It is about twice as common in men as in women, with a male to female ratio of 1.5 to 2.0:1. 8,14 Age, sex, ethnicity, extent of skin disease, primary lesion type, response to initial therapy and histologic morphology for PCALCL is not predictive of disease progression or worse survival.…”

Section: Discussionmentioning

confidence: 99%

“…4,14,15 It is about twice as common in men as in women, with a male to female ratio of 1.5 to 2.0:1. 8,14 Age, sex, ethnicity, extent of skin disease, primary lesion type, response to initial therapy and histologic morphology for PCALCL is not predictive of disease progression or worse survival. 14 Our patient is classified as stage T2aN0M0 based on the TNM classification system for primary cutaneous lymphomas other than MF/SS of the ISCL/EORTC.…”

Section: Discussionmentioning

confidence: 99%

“…8,14 Age, sex, ethnicity, extent of skin disease, primary lesion type, response to initial therapy and histologic morphology for PCALCL is not predictive of disease progression or worse survival. 14 Our patient is classified as stage T2aN0M0 based on the TNM classification system for primary cutaneous lymphomas other than MF/SS of the ISCL/EORTC. 2 It has a favorable prognosis with 5-and 10-year survival rate of 91 to 100% and 68.6 to 78%, respectively.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Primary cutaneous CD30+ anaplastic large cell lymphoma: report of a rare case

Chao-Lo¹,

King-Ismael²,

Lopez³

2008

J Dermatol Case Rep

View full text Add to dashboard Cite

Primary cutaneous anaplastic large cell lymphoma (PCALCL) is a rare type of non-Hodgkin's lymphoma comprising approximately 0.9-9.0% of all cutaneous lymphomas. PCALCL is characterized by the absence of systemic involvement, spontaneous regression and low recurrence rate especially in localized lesions.We present a 47-year-old female with a 1½-year history of two asymptomatic erythematous indurated plaques on the right arm. Skin punch biopsy revealed dense infiltrates of non-epidermotropic, large, irregularly-shaped lymphocytes with hyperchromatic and pyknotic nuclei. Immunohistochemistry revealed that these atypical cells are anaplastic lymphoma kinase (ALK) positive, CD30+, CD3-, CD20-and epithelial membrane antigen (EMA) negative. Clinical, histopathological and immunohistochemical findings are consistent with PCALCL. Work-ups revealed no systemic involvement. Short course CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) chemotherapy resulted in total resolution of skin lesions; however, recurrence was noted 12 months after treatment. She then underwent radiotherapy and achieved complete remission.Because the clinical presentation of PCALCL can be variable, a high index of suspicion is necessary in patients presenting with chronic plaques and nodules unresponsive to topical or oral medications.

show abstract

Section: Discussionmentioning

confidence: 99%

“…5,8,[13][14][15] PCALCL is uncommon before age 20, with a peak at age 60. 4,14,15 It is about twice as common in men as in women, with a male to female ratio of 1.5 to 2.0:1.…”

Section: Discussionmentioning

confidence: 99%